Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

Primarily a grantmaking agency with an $8 billion budget, SAMHSA channels funds and training that the federal government ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of ...